Accessibility Menu
Genprex logo

Genprex(NASDAQ) GNPX

Current Price$7.85
Market Cap$3.78MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2018)-100%
5 Year-100%
1 Year-97%
1 Month-35%
Genprex last closing stock price
MetricPriceDate
Last closeUSD 7.492026-07-23
Genprex stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-6.37%USD 8.002026-07-16
1 month-34.65%USD 11.462026-06-23
3 month-66.62%USD 22.442026-04-24
Year to date-80.55%USD 38.502025-12-31
1 year-97.35%USD 282.482025-07-23
3 year-99.98%USD 34,584.002023-07-24
5 year-99.99%USD 134,640.002021-07-23
Since inception-100%USD 206,800.662018-03-29

Genprex Financials at a Glance

Market Cap

$3.78MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$16.73M

EPS (TTM)

-$335.72

P/E Ratio

-0.02

Dividend

$0.00

Beta (Volatility)

1.24 (Average)

Price

$7.85

Volume

413

Open

$7.39

Previous Close

$7.49

Daily Range

$7.39 - $7.88

52-Week Range

$6.72 - $1,210.00

Estimated Earnings Date

Sep 2, 2026

GNPX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Genprex

Genprex develops gene therapies for cancer and diabetes patients. Its treatments aim to help those with hard-to-treat lung cancer or diabetes. The company’s work targets people who need new options when standard treatments fail.

Gene Therapy Toolbox: What’s Inside?

  • REQORSA (GPX-001): Gene therapy for lung cancer, targeting patients with limited treatment options. (0% of revenue; pre-commercial)
  • GPX-002: Early-stage gene therapy for both Type 1 and Type 2 diabetes. (0% of revenue; pre-commercial)
  • ONCOPREX Delivery System: Non-viral technology for delivering gene therapies throughout the body.
  • Intellectual Property: 12 granted patents and 25 pending applications worldwide, covering gene therapy technologies.
  • Convergen Biotech: Subsidiary focused on developing and commercializing diabetes gene therapies.

Growth Spurts and Strategic Moves

  • Formed Convergen Biotech in 2025 to advance diabetes therapies separately.
  • Secured new and amended licensing deals in 2024-2025 with University of Pittsburgh, University of Michigan, NYU, and UTHealth Houston.
  • Launched Acclaim-1 and Acclaim-3 clinical trials for lung cancer in 2024-2025.
  • Closed Acclaim-2 trial in 2025 to focus resources on higher-priority programs.
  • Entered a $12.5 million equity line of credit with Lincoln Park Capital in June 2025.

What Makes Genprex Stand Out?

Genprex uses a non-viral delivery system, aiming to avoid some risks of traditional gene therapy. Its focus on combining gene therapy with existing cancer drugs targets patients with few remaining options.

Five Things You Need to Know

  • No revenue reported for the six months ended June 30, 2025.
  • Net loss was $8.6 million in H1 2025, down 31% from H1 2024.
  • Cash and equivalents were $1.35 million as of June 30, 2025.
  • Fifteen full-time employees as of June 30, 2025, down from 21 a year earlier.
  • Substantial doubt exists about the company’s ability to continue without new funding.

Bottom Line

Genprex remains a pre-revenue biotech focused on gene therapies for cancer and diabetes. Its future depends on clinical progress and securing additional funding.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

13

CEO

Ryan M. Confer

Website

www.genprex.com

Headquarters

Austin, TX 78746, US

GNPX Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-247.33%

Return on Capital

-194.87%

Return on Assets

-82.37%

Earnings Yield

-50.00%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$3.78MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

504.90K

Volume

413

Avg. Volume

23.66K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$16.04M

EBITDA

-$15.98M

Operating Cash Flow

-$14.29M

Capital Expenditure

-$0.00

Free Cash Flow

-$14.29M

Cash & ST Invst.

$18.05M

Total Debt

$0.00

Genprex Performance Analysis

Genprex annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Genprex sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Genprex annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -21,783.9612.8%
20232023-12-31USD -24,819.0813.9%
20242024-12-31USD -5,871.58-76.3%
20252025-12-31USD -382.79-93.5%
Genprex sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3034.6%
Q32025-09-3041.2%
Q42025-12-3177.0%
Q12026-03-3144.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$3.78MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$290.92K

N/A

Employees

13

N/A

Net Income

-$4.46M

-12.5%

EBITDA

-$4.46M

-12.5%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$18.05M

+420.4%

Total Debt

$0.00

N/A

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-82.37%

N/A

Return on Invested Capital

-94.62%

N/A

Free Cash Flow

-$3.14M

+24.6%

Operating Cash Flow

-$3.14M

+24.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
INMInMed Pharmaceuticals Inc.
$1.86+0.54%
LIMNLiminatus Pharma, Inc. Class A Common Stock
$0.12-2.70%
CNSPCNS Pharmaceuticals, Inc.
$5.35-1.11%
BDRXBiodexa Pharmaceuticals Plc
$1.70+1.19%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.27-0.06%
AALAmerican Airlines Group
$14.40+0.06%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$43.93+0.02%
PATHUiPath
$10.81+0.06%

Questions About GNPX

What is the current price of Genprex?

Genprex is trading at $7.85 per share.

What is the 52-week range for Genprex?

Over the past 52 weeks, Genprex has traded between $6.72 and $1,210.00.

How much debt does Genprex have?

As of the most recent reporting period, Genprex reported total debt of $0.00.

How much cash does Genprex have on hand?

Genprex reported $18.05M in cash and cash equivalents in its most recent financial results.

What is Genprex’s dividend yield?

Genprex does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services